Immunoglobulin Or Antibody Binds A Specifically Identified Amino Acid Sequence Patents (Class 435/331)
  • Antibodies that bind to OX40 and their uses
    Publication number: 20130183315
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Application
    Filed: July 10, 2012
    Publication date: July 18, 2013
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Antoine Attinger, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
  • AGONISTIC ANTIBODY TO CD27
    Publication number: 20130183316
    Abstract: The invention relates to a binding compound, which binds the same epitope of human CD27 as monoclonal antibody hCD27.15, produced by hybridoma hCD27.15 which was deposited with the ATCC in on Jun. 2, 2010 under number PTA-11008. In particular the invention relates to such a binding compound of claim 1 which may comprise: an antibody heavy chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 5, 6 and 7, or a variant of any of said sequences; and/or an antibody light chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 8, 9 and 10, or a variant of any of said sequences.
    Type: Application
    Filed: December 19, 2012
    Publication date: July 18, 2013
    Applicant: BIONOVION HOLDING B.V.
    Inventor: Bionovion Holding B.V.
  • HIGH AFFINITY ANTIBODIES THAT NEUTRALIZE STAPHYLOCOCCUS ENTEROTOXIN B
    Publication number: 20130183314
    Abstract: This invention provides antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.
    Type: Application
    Filed: July 2, 2012
    Publication date: July 18, 2013
    Applicant: MORPHOTEK, INC.
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
  • Polynucleotides encoding antibodies against sclerostin and uses therefor
    Patent number: 8486661
    Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: July 16, 2013
    Assignee: Novartis AG
    Inventors: Michaela Kniessel, Christine Halleux, Shou-Ih Hu, Beate Diefenbach-Streiber, Josef Prassler
  • METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING DISEASES
    Publication number: 20130177566
    Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.
    Type: Application
    Filed: November 6, 2012
    Publication date: July 11, 2013
    Applicant: CELERA CORPORATION
    Inventor: Celera Corporation
  • PDGF RECEPTOR BETA BINDING POLYPEPTIDES
    Publication number: 20130177572
    Abstract: The present invention provides binding polypeptides (e.g., antibodies or fragments thereof) that specifically bind to a target antigen (e.g., a human antigen, e.g., human PDGFR?) with high affinity. The invention also provides, libraries of binding polypeptides, pharmaceutical compositions, as well as nucleic acids encoding binding polypeptides, recombinant expression vectors and host cells for making such binding polypeptides. Methods of using binding polypeptide of the invention to diagnose and treat disease are also encompassed by the invention.
    Type: Application
    Filed: December 5, 2012
    Publication date: July 11, 2013
    Applicant: X-Body, Inc.
    Inventors: Yan CHEN, Richard W. Wagner, Csaba Pazmany
  • NOVEL C3C EPITOPE, ANTIBODIES BINDING THERETO, AND USE THEREOF
    Publication number: 20130177567
    Abstract: Provided are antibodies directed against a novel epitope on the human C3c (complement factor 3 c) and the use and manufacture thereof. Moreover, there is provided a novel immunogen for use in the preparation of the antibodies. The antibodies are in the first place of the monoclonal type.
    Type: Application
    Filed: May 17, 2011
    Publication date: July 11, 2013
    Applicant: Sydansk Universitet
    Inventors: Mikkel Ole Skjoedt, Lars Vitved, Yaseelan Palarasah
  • NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE
    Publication number: 20130171147
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 002-H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
    Type: Application
    Filed: November 18, 2010
    Publication date: July 4, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder
  • Anti-ANGPTL3 Antibodies and Uses Thereof
    Publication number: 20130171149
    Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.
    Type: Application
    Filed: June 14, 2012
    Publication date: July 4, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Mark W. Sleeman, Viktoria Gusarova, Andrew J. Murphy
  • ANTIBODIES TO MUC16 AND METHODS OF USE THEREOF
    Publication number: 20130171152
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.
    Type: Application
    Filed: March 25, 2011
    Publication date: July 4, 2013
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: David Spriggs, Dharmarao Thapi
  • Novel JNK Inhibitor Molecules
    Publication number: 20130172530
    Abstract: The present invention relates to novel JNK inhibitor molecules. The present invention furthermore relates to methods for raising antibodies against such JNK inhibitor molecules as well as to the respective antibodies and cells producing said antibodies.
    Type: Application
    Filed: June 21, 2011
    Publication date: July 4, 2013
    Applicant: XIGEN S.A.
    Inventor: Christophe Bonny
  • Inhibitors Of Complement Activation
    Publication number: 20130171155
    Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.
    Type: Application
    Filed: February 5, 2013
    Publication date: July 4, 2013
    Applicant: GENENTECH, INC.
    Inventor: GENENTECH, INC.
  • ANTI-DR4 AGONIST ANTIBODIES
    Publication number: 20130156781
    Abstract: The present invention provides antibodies and antibody fragments that specifically recognize and agonize the death receptor 4 (DR4). Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.
    Type: Application
    Filed: June 16, 2011
    Publication date: June 20, 2013
    Applicant: The Govt. of the United States of America H.H.N.I. H., Office of Technology Transfer
    Inventors: Dimiter Dimitrov, Yang Feng
  • Annexin 1 Antibody
    Publication number: 20130156780
    Abstract: The present invention provides a specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence shown in FIG. 2A. The present invention also relates to the sue of such a specific binding molecule in the treatment of T cell-mediated disease.
    Type: Application
    Filed: June 9, 2011
    Publication date: June 20, 2013
    Inventors: Fulvio D'Acquisto, Mauro Perretti
  • NOVEL ANTIGEN BINDING PROTEINS
    Publication number: 20130156779
    Abstract: The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3.
    Type: Application
    Filed: September 2, 2011
    Publication date: June 20, 2013
    Inventors: Neil James Clarke, Kyung Oh Johanson, Zdenka Ludmila Jonak, Alexander H. Taylor, Christopher B. Hopson, Stephen H. Trulli, Zdenka Haskova, Judithann M. Lee, John R. White, Yu Xue
  • Monoclonal Antibodies for Treatment of Cancer
    Publication number: 20130156782
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
    Type: Application
    Filed: December 11, 2012
    Publication date: June 20, 2013
    Inventors: Ugur Sahin, Michael Koslowski, Ozlem Tureci
  • MONOCLONAL ANTIBODY AGAINST GROUP 2 ALLERGEN OF DERMATOPHAGOIDES PTERONYSSIUNS, HYBRIDOMA CELL LINE PRODUCING THEREOF, STRIP, KIT AND METHOD USING SAID MONOCLONAL ANTIBODY FOR DUST MITE ASSAY
    Publication number: 20130143242
    Abstract: This present invention discloses a monoclonal antibody which specifically recognizes and binds to a epitope of group 2 allergen of Dermatophagoides pteronyssiuns, usually named Der p 2, and a hybridoma cell line producing thereof. Furthermore, this invention also discloses a strip, kit and method utilizing said monoclonal antibody for the detection of the presence of dust mite allergens and the calculation of dust mite number in the environment.
    Type: Application
    Filed: November 15, 2012
    Publication date: June 6, 2013
    Applicant: TAICHUNG VETERANS GENERAL HOSPITAL
    Inventor: Taichung Veterans General Hospital
  • NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE
    Publication number: 20130129739
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
    Type: Application
    Filed: November 18, 2010
    Publication date: May 23, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christiane Ottto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
  • Group B Streptococcus Polypeptides Nucleic Acids and Therapeutic Compositions and Vaccines Thereof
    Publication number: 20130129737
    Abstract: This invention provides an isolated nucleic acid encoding a polypeptide comprising amino acid sequences of a streptococcal matrix adhesion E (EmaE) polypeptide. Antibodies to the EmaE polypeptide and immunogenic fragments thereof are also provided. This invention provides pharmaceutical compositions, immunogenic compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptide, antibodies thereto, and nucleic acids.
    Type: Application
    Filed: February 18, 2011
    Publication date: May 23, 2013
    Applicants: University of Utah Research Foundation, St. Jude Children's Research Hospital
    Inventors: Elisabeth Adderson, John Bohnsack
  • ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
    Publication number: 20130129743
    Abstract: The invention provides anti-HtrA1 antibodies and methods of using the same.
    Type: Application
    Filed: October 12, 2012
    Publication date: May 23, 2013
    Applicant: GENENTECH, INC.
    Inventor: GENENTECH, INC.
  • ANTIBODIES TO EGFL7 AND METHODS FOR THEIR USE
    Publication number: 20130129735
    Abstract: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: January 31, 2013
    Publication date: May 23, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • RECOMBINANT PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEINS 4 AND 5 AND THEIR USE
    Publication number: 20130129766
    Abstract: Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.
    Type: Application
    Filed: November 1, 2012
    Publication date: May 23, 2013
    Inventors: Shirley LONGACRE, Hannah POLSON, Ronald PERRAUT, Faridabano NATO
  • BINDING AGENTS
    Publication number: 20130121997
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Application
    Filed: November 30, 2012
    Publication date: May 16, 2013
    Applicant: AMGEN INC.
    Inventor: Amgen Inc.
  • NOVEL ANTIGEN BINDING PROTEINS
    Publication number: 20130123472
    Abstract: Antigen binding proteins, such as antibodies, which bind to human MAGE-A3, polynucleotides encoding such antigen binding proteins, and uses and manufacture thereof.
    Type: Application
    Filed: July 20, 2011
    Publication date: May 16, 2013
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Alain Bergeron, Normand Blais, Remi M. Palmantier, Anthony Pilorget, Yves Fradet
  • ANTIBODIES AGAINST HMGB1 AND FRAGMENTS THEREOF
    Publication number: 20130115217
    Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to particular fragments of HMGB1, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade, methods of detecting and/or identifying an agent that binds to an HMGB1 polypeptide or fragment thereof, and methods of detecting HMGB1 in a sample.
    Type: Application
    Filed: January 8, 2013
    Publication date: May 9, 2013
    Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventor: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
  • Human Monoclonal Antibodies to Human Nucleolin
    Publication number: 20130115674
    Abstract: The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysi-ology of the disease.
    Type: Application
    Filed: November 17, 2010
    Publication date: May 9, 2013
    Applicant: Musc Foundation for Research Development
    Inventors: Natalie Sutkowski, Daniel Fernandes, Brian Hoel, Semyon Rubinchik
  • COLON DISEASE TARGETS AND USES THEREOF
    Publication number: 20130111613
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
    Type: Application
    Filed: September 17, 2012
    Publication date: May 2, 2013
    Applicant: CELERA CORPORATION
    Inventors: Yeounjin KIM, Tao HE, Steve RUBEN
  • NOVEL ANTIBODY FOR THE DIAGNOSIS AND/OR PROGNOSIS OF CANCER
    Publication number: 20130102494
    Abstract: The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to novel antibodies capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding process, for detecting and diagnosing pathological hyperproliferative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the over expression of c Met. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers.
    Type: Application
    Filed: June 29, 2011
    Publication date: April 25, 2013
    Inventor: Alexandra Jouhanneaud
  • METHODS AND COMPOSITIONS BASED ON SHIGA TOXIN TYPE 1 PROTEIN
    Publication number: 20130101591
    Abstract: The invention is based on the discovery of the epitope in the Stx1 protein for the 13C4 antibody. The invention features non-full length Stx1 polypeptides that include the epitope for the 13C4 monoclonal antibody epitope. The invention also features methods of producing anti-Stx1 antibodies specific for the 13C4 epitope of the Stx1 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 13C4 epitope or with an anti-Stx1 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx1 in a sample using the antibodies developed using the methods of the invention.
    Type: Application
    Filed: October 5, 2012
    Publication date: April 25, 2013
    Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventor: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
  • ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L
    Publication number: 20130095109
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Application
    Filed: October 12, 2012
    Publication date: April 18, 2013
    Applicants: DOMANTIS LIMITED, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Bristol-Myers Squibb Company, Domantis Limited
  • BIOMARKER SPECIFIC TO BRAIN/NERVE OR SPECIFIC TO NEURONAL DIFFERENTIATION
    Publication number: 20130095107
    Abstract: The invention provides a novel polypeptide and a specific partial peptide thereof, as well as a novel polynucleotide and a specific partial nucleotide thereof, that can be used as a biomarker specific for the brain/nerves or specific for nerve differentiation; an expression vector for such a polynucleotide and a specific partial peptide thereof; a transformant incorporating such an expression vector; an antisense molecule, RNAi-inducing nucleic acid (e.g., siRNA), aptamer, or antibody for such a biomarker, and a composition comprising the same; a mammalian cell or non-human mammal wherein the expression or a function of such a biomarker is regulated; a measuring means (e.g., primer set, nucleic acid probe, antibody, aptamer) for such a biomarker, and a reagent comprising the same and the like.
    Type: Application
    Filed: December 13, 2011
    Publication date: April 18, 2013
    Inventors: Ai WAKAMATSU, Junichi YAMAMOTO, Takao ISOGAI
  • Recombinant adhesin protein and methods and uses thereof
    Patent number: 8420090
    Abstract: Isolated and/or recombinant adhesin polypeptides from Burkholderia pseudomallei are provided, which are used as vaccines. Genetic constructs comprising nucleic acid sequences encoding such polypeptides are also provided. Vectors comprising such constructs have been prepared and used for transforming host cells for producing the polypeptides of the invention. Antibodies to such polypeptides are also provided. Such antibodies can be used to detect the presence of B. pseudomallei or B. mallei and in methods of treating or preventing Burkholderia infection.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: April 16, 2013
    Assignee: Her Majesty the Queen in Right of Canada as Represented by the Minister of National Defence
    Inventors: Chad Wesley Stratilo, Scott James Jager
  • ANTI-HUMAN TROP-2 ANTIBODY HAVING ANTI-TUMOR ACTIVITY IN VIVO
    Publication number: 20130089872
    Abstract: The present invention provides: an antibody, which specifically reacts with hTROP-2 and has anti-tumor activity in vivo; a hybridoma, which produces the aforementioned antibody; a complex of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor.
    Type: Application
    Filed: May 17, 2011
    Publication date: April 11, 2013
    Applicant: LIVTECH, INC.
    Inventors: Koji Nakamura, Kentaro Okamura, Maki Tamura, Hiroyuki Yanai, Toru Kanke
  • BINDING MEMBERS FOR HUMAN CYTOMEGALOVIRUS
    Publication number: 20130089559
    Abstract: The invention relates to binding members, especially antibody molecules, which may neutralise the biological effects of human cytomegalovirus (hCMV). The binding members may be useful for the treatment and prophylaxis of hCMV infection.
    Type: Application
    Filed: June 22, 2012
    Publication date: April 11, 2013
    Applicant: 4-Antibody AG
    Inventors: Ulf Grawunder, Michael Mach, Luis Martin-Parras, Sonja Pötzsch, Nadja Spindler, Heinrich Sticht, Anna-Katharina Wiegers, Thomas Winkler
  • Anti-amyloid antibodies and uses thereof
    Patent number: 8414893
    Abstract: Compositions for treating neurodegenerative or amyloidogenic disorders such as Alzheimer's disease (AD) are provided. More particularly, anti-amyloid-beta antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: April 9, 2013
    Assignee: Amgen Inc.
    Inventors: Anja Leona Biere-Citron, Frederick W. Jacobsen, Stephen J. Wood
  • CANCER TARGETS AND USES THEREOF
    Publication number: 20130078253
    Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.
    Type: Application
    Filed: March 30, 2012
    Publication date: March 28, 2013
    Applicant: CELERA CORPORATION
    Inventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
  • LINGO binding molecules and Pharmaceutical Use Thereof
    Publication number: 20130071400
    Abstract: The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with axonal degeneration and demyelination.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: NOVARTIS AG
    Inventors: Adrian Walmsley, William Leonard Wishart, Marta Cortes-Cros, Josef Prassler, Ingo Klagge
  • Anti-C5 Alpha Antibodies
    Publication number: 20130071922
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 21, 2013
    Applicant: Adienne SRL
    Inventors: Francesco TEDESCO, Roberto Marzari
  • Human CGRP Receptor Binding Proteins
    Publication number: 20130071410
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related, disorders including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 21, 2013
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, JR., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER
    Publication number: 20130071325
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.
    Type: Application
    Filed: March 10, 2011
    Publication date: March 21, 2013
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Rita Mitnacht-Kraus
  • Anti-ligand (thromobpoietin) antibodies
    Patent number: 8399250
    Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocyte progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.
    Type: Grant
    Filed: April 27, 1995
    Date of Patent: March 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Frederic J. De Sauvage
  • Peptides for development of diagnostic and therapeutic agents and methods of using same
    Patent number: 8399202
    Abstract: Novel immuno-interactive fragments of the ?C portion of a mammalian inhibin ? subunit, together with their variants and derivatives, produce antigen-binding molecules that are interactive with the ?C portion, and which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention can be used for the detection of a mammalian inhibin and for the treatment and/or prevention of conditions associated with aberrant levels of a mammalian inhibin.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: March 19, 2013
    Assignee: Prince Henry's Institute of Medical Research
    Inventors: David Mark Milne-Robertson, Peter Gordon Stanton, Nicholas Francis Cahir
  • COLON CANCER TARGETS AND USES THEREOF
    Publication number: 20130067608
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
    Type: Application
    Filed: August 16, 2012
    Publication date: March 14, 2013
    Applicant: CELERA CORPORATION
    Inventors: Bruno DOMON, Aiqun LI, Tao HE, Ian MCCAFFERY
  • INTEGRIN ALPHA-V BETA8 NEUTRALIZING ANTIBODY
    Publication number: 20130064837
    Abstract: The present invention relates to ???8 antagonists, anti-???8 antibodies or immunoconjugates for reducing TGF? activation in an individual. Further provided are compositions comprising one of the ???8 antagonists, anti-???8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter.
    Type: Application
    Filed: February 18, 2011
    Publication date: March 14, 2013
    Applicant: The Regents of the University of California
    Inventors: Stephen Nishimura, Jianlong Lou, Jody Lynn Baron, James D. Marks
  • Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization
    Publication number: 20130064829
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Application
    Filed: November 6, 2012
    Publication date: March 14, 2013
    Applicant: UCB MANUFACTURING, INC.
    Inventor: UCB MANUFACTURING, INC.
  • Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization
    Publication number: 20130064830
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Application
    Filed: November 6, 2012
    Publication date: March 14, 2013
    Applicant: UCB MANUFACTURING, INC.
    Inventor: UCB MANUFACTURING, INC.
  • ANTI-PDEF ANTIBODIES AND USES THEREOF
    Publication number: 20130058966
    Abstract: The present invention relates to an isolated antibody or antigen-binding fragment thereof that specifically binds with high affinity to at least a portion of a segment of human prostate-derived Ets transcription factor (PDEF). The anti-PDEF antibody of the present invention is effective in prognostic and diagnostic assays for detecting PDEF with immunohistochemistry. The present invention also relates to methods of making the anti-PDEF antibody disclosed herein. The present invention further relates to vaccines against cancers associated with positive expression of PDEF, as well as methods for treating those cancers. Vectors, diagnostic kits, and hybridomas are also disclosed.
    Type: Application
    Filed: August 17, 2012
    Publication date: March 7, 2013
    Inventor: Ashwani SOOD
  • Antigenic GM-CSF Peptides and Antibodies to GM-CSF
    Publication number: 20130058945
    Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.
    Type: Application
    Filed: October 24, 2012
    Publication date: March 7, 2013
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
  • COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
    Publication number: 20130058960
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 2, 2012
    Publication date: March 7, 2013
    Applicant: GENENTECH, INC.
    Inventor: Genentech, Inc.
  • ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE
    Publication number: 20130058955
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Application
    Filed: August 6, 2012
    Publication date: March 7, 2013
    Applicant: GENENTECH, INC.
    Inventors: Robert F. Kelley, Vishva Dixit, Marissa L. Matsumoto